BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

791 related articles for article (PubMed ID: 30145781)

  • 1. The Role of Oncolytic Viruses in the Treatment of Melanoma.
    Bayan CY; Lopez AT; Gartrell RD; Komatsubara KM; Bogardus M; Rao N; Chen C; Hart TD; Enzler T; Rizk EM; Pradhan JS; Marks DK; Geskin LJ; Saenger YM
    Curr Oncol Rep; 2018 Aug; 20(10):80. PubMed ID: 30145781
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Talimogene laherparepvec (T-VEC) as cancer immunotherapy.
    Kohlhapp FJ; Zloza A; Kaufman HL
    Drugs Today (Barc); 2015 Sep; 51(9):549-58. PubMed ID: 26488034
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intratumoral Immunotherapy-Update 2019.
    Hamid O; Ismail R; Puzanov I
    Oncologist; 2020 Mar; 25(3):e423-e438. PubMed ID: 32162802
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Talimogene Laherparepvec: An Oncolytic Virus Therapy for Melanoma.
    Corrigan PA; Beaulieu C; Patel RB; Lowe DK
    Ann Pharmacother; 2017 Aug; 51(8):675-681. PubMed ID: 28351167
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New hopes for the breast cancer treatment: perspectives on the oncolytic virus therapy.
    Chowaniec H; Ślubowska A; Mroczek M; Borowczyk M; Braszka M; Dworacki G; Dobosz P; Wichtowski M
    Front Immunol; 2024; 15():1375433. PubMed ID: 38576614
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The safety of talimogene laherparepvec for the treatment of advanced melanoma.
    Gangi A; Zager JS
    Expert Opin Drug Saf; 2017 Feb; 16(2):265-269. PubMed ID: 27989216
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical development of talimogene laherparepvec (T-VEC): a modified herpes simplex virus type-1-derived oncolytic immunotherapy.
    Harrington KJ; Puzanov I; Hecht JR; Hodi FS; Szabo Z; Murugappan S; Kaufman HL
    Expert Rev Anticancer Ther; 2015; 15(12):1389-403. PubMed ID: 26558498
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An Update on the Role of Talimogene Laherparepvec (T-VEC) in the Treatment of Melanoma: Best Practices and Future Directions.
    Larocca CA; LeBoeuf NR; Silk AW; Kaufman HL
    Am J Clin Dermatol; 2020 Dec; 21(6):821-832. PubMed ID: 32767272
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular Pathways: Mechanism of Action for Talimogene Laherparepvec, a New Oncolytic Virus Immunotherapy.
    Kohlhapp FJ; Kaufman HL
    Clin Cancer Res; 2016 Mar; 22(5):1048-54. PubMed ID: 26719429
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oncolytic virotherapy evolved into the fourth generation as tumor immunotherapy.
    Wang X; Shen Y; Wan X; Hu X; Cai WQ; Wu Z; Xin Q; Liu X; Gui J; Xin HY; Xin HW
    J Transl Med; 2023 Jul; 21(1):500. PubMed ID: 37491263
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Talimogene laherparepvec treatment to overcome loco-regional acquired resistance to immune checkpoint blockade in tumor stage IIIB-IV M1c melanoma patients.
    Fröhlich A; Niebel D; Fietz S; Egger E; Buchner A; Sirokay J; Landsberg J
    Cancer Immunol Immunother; 2020 May; 69(5):759-769. PubMed ID: 32052079
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Talimogene Laherparepvec (T-VEC): A Review of the Recent Advances in Cancer Therapy.
    Zhang T; Jou TH; Hsin J; Wang Z; Huang K; Ye J; Yin H; Xing Y
    J Clin Med; 2023 Jan; 12(3):. PubMed ID: 36769745
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Review of talimogene laherparepvec: A first-in-class oncolytic viral treatment of advanced melanoma.
    Haitz K; Khosravi H; Lin JY; Menge T; Nambudiri VE
    J Am Acad Dermatol; 2020 Jul; 83(1):189-196. PubMed ID: 32004650
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Talimogene Laherparepvec (T-VEC) and Other Oncolytic Viruses for the Treatment of Melanoma.
    Bommareddy PK; Patel A; Hossain S; Kaufman HL
    Am J Clin Dermatol; 2017 Feb; 18(1):1-15. PubMed ID: 27988837
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An evaluation of talimogene laherparepvec for the treatment of melanoma.
    Broman KK; Zager JS
    Expert Opin Biol Ther; 2020 Jan; 20(1):9-14. PubMed ID: 31690129
    [No Abstract]   [Full Text] [Related]  

  • 16. Therapy with oncolytic viruses: progress and challenges.
    Shalhout SZ; Miller DM; Emerick KS; Kaufman HL
    Nat Rev Clin Oncol; 2023 Mar; 20(3):160-177. PubMed ID: 36631681
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combining talimogene laherparepvec with immunotherapies in melanoma and other solid tumors.
    Dummer R; Hoeller C; Gruter IP; Michielin O
    Cancer Immunol Immunother; 2017 Jun; 66(6):683-695. PubMed ID: 28238174
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combining Tumor Vaccination and Oncolytic Viral Approaches with Checkpoint Inhibitors: Rationale, Pre-Clinical Experience, and Current Clinical Trials in Malignant Melanoma.
    Cavalcante L; Chowdhary A; Sosman JA; Chandra S
    Am J Clin Dermatol; 2018 Oct; 19(5):657-670. PubMed ID: 29961183
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Talimogene laherparepvec (T-VEC) for the treatment of advanced melanoma.
    Johnson DB; Puzanov I; Kelley MC
    Immunotherapy; 2015; 7(6):611-9. PubMed ID: 26098919
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Talimogene laherparepvec (T-Vec) for the treatment of melanoma and other cancers.
    Grigg C; Blake Z; Gartrell R; Sacher A; Taback B; Saenger Y
    Semin Oncol; 2016 Dec; 43(6):638-646. PubMed ID: 28061981
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 40.